AFT Pharmaceuticals Limited (ASX: AFP)
Australia
· Delayed Price · Currency is AUD 2.550
0.00 (0.00%)
Dec 20, 2024, 11:29 AM AEST
AFT Pharmaceuticals Income Statement
Financials in millions NZD. Fiscal year is April - March.
Millions NZD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
| Revenue | 198.51 | 195.41 | 156.64 | 130.31 | 113.11 | 105.6 | Upgrade
|
| Revenue Growth (YoY) | 13.76% | 24.75% | 20.20% | 15.22% | 7.11% | 24.05% | Upgrade
|
| Cost of Revenue | 109.98 | 107.14 | 83.66 | 68.54 | 64.36 | 57.33 | Upgrade
|
| Gross Profit | 88.54 | 88.27 | 72.98 | 61.78 | 48.74 | 48.27 | Upgrade
|
| Selling, General & Admin | 61.53 | 58.09 | 49.4 | 37.99 | 36.69 | 37.3 | Upgrade
|
| Research & Development | 8.27 | 6.47 | 3.91 | 3.62 | 1.97 | - | Upgrade
|
| Other Operating Expenses | -0.44 | -0.53 | - | -0.23 | -0.63 | -0.54 | Upgrade
|
| Operating Expenses | 69.35 | 64.04 | 53.31 | 41.39 | 38.03 | 36.76 | Upgrade
|
| Operating Income | 19.18 | 24.24 | 19.67 | 20.39 | 10.71 | 11.5 | Upgrade
|
| Interest Expense | -3.23 | -3.69 | -2.87 | -2.44 | -3.44 | -6.96 | Upgrade
|
| Interest & Investment Income | 0.06 | 0.07 | 0.01 | 0 | 0 | 0.02 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.11 | 1.11 | -3.14 | 0.64 | 0.24 | -2.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.1 | 0.3 | 2.13 | 0.09 | 0.38 | 0.73 | Upgrade
|
| EBT Excluding Unusual Items | 17.21 | 22.02 | 15.8 | 18.69 | 7.89 | 3.09 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 9.78 | Upgrade
|
| Pretax Income | 17.21 | 22.02 | 15.8 | 18.69 | 7.89 | 12.88 | Upgrade
|
| Income Tax Expense | 5.88 | 6.41 | 5.15 | -1.16 | 0.11 | 0.19 | Upgrade
|
| Net Income | 11.61 | 15.61 | 10.65 | 19.85 | 7.78 | 12.69 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.19 | 0.99 | Upgrade
|
| Net Income to Common | 11.61 | 15.61 | 10.65 | 19.85 | 7.59 | 11.7 | Upgrade
|
| Net Income Growth | 6.25% | 46.51% | -46.32% | 155.05% | -38.69% | - | Upgrade
|
| Shares Outstanding (Basic) | 114 | 105 | 105 | 105 | 103 | 97 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 105 | 105 | 105 | 103 | 97 | Upgrade
|
| Shares Change (YoY) | 56.43% | 0.02% | 0.16% | 1.34% | 6.15% | 0.00% | Upgrade
|
| EPS (Basic) | 0.10 | 0.15 | 0.10 | 0.19 | 0.07 | 0.12 | Upgrade
|
| EPS (Diluted) | 0.10 | 0.15 | 0.10 | 0.19 | 0.07 | 0.12 | Upgrade
|
| EPS Growth | -32.08% | 46.48% | -46.41% | 168.07% | -39.61% | - | Upgrade
|
| Free Cash Flow | 25.56 | 28.75 | 11.43 | 13.82 | 0.66 | 14.79 | Upgrade
|
| Free Cash Flow Per Share | 0.22 | 0.27 | 0.11 | 0.13 | 0.01 | 0.15 | Upgrade
|
| Dividend Per Share | 0.016 | 0.016 | 0.011 | - | - | - | Upgrade
|
| Dividend Growth | 45.45% | 45.45% | - | - | - | - | Upgrade
|
| Gross Margin | 44.60% | 45.17% | 46.59% | 47.40% | 43.09% | 45.71% | Upgrade
|
| Operating Margin | 9.66% | 12.40% | 12.56% | 15.65% | 9.47% | 10.89% | Upgrade
|
| Profit Margin | 5.85% | 7.99% | 6.80% | 15.23% | 6.71% | 11.08% | Upgrade
|
| Free Cash Flow Margin | 12.87% | 14.71% | 7.30% | 10.61% | 0.58% | 14.00% | Upgrade
|
| EBITDA | 19.82 | 24.63 | 19.88 | 20.67 | 10.97 | 11.77 | Upgrade
|
| EBITDA Margin | 9.98% | 12.61% | 12.69% | 15.86% | 9.70% | 11.14% | Upgrade
|
| D&A For EBITDA | 0.64 | 0.4 | 0.21 | 0.28 | 0.26 | 0.26 | Upgrade
|
| EBIT | 19.18 | 24.24 | 19.67 | 20.39 | 10.71 | 11.5 | Upgrade
|
| EBIT Margin | 9.66% | 12.40% | 12.56% | 15.65% | 9.47% | 10.89% | Upgrade
|
| Effective Tax Rate | 34.13% | 29.11% | 32.57% | - | 1.33% | 1.44% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.